In addition, the prognostic significance of the subgroup of the SDG SLC2A12 based on the SPE and gene expression are 0.022 and 0.47, respectively, which means that the different subgroups obtained based on the SPE can stratify breast cancer patients into subgroups with different survival times well from the viewpoint of statistics, while the gene expression failed. This evidence concerns the gene SLC2A12 and breast carcinoma.